Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: T L Comiskey who wrote (183)	3/2/2000 3:43:00 PM
From: T L Comiskey	Respond to of 370

Thursday March 2, 2:44 pm Eastern Time Vion says cancer drug Phase I test completed NEW HEAVEN, Conn., March 2 (Reuters) - Drug maker Vion Pharmaceuticals Inc. (NasdaqNM:VION - news) on Thursday said it has completed a Phase I study of a cancer treatment. The treatment, Triapine, works by blocking a critical step in the synthesis of DNA, preventing the replication of tumor cells. The Phase I study was designed to assess Triapine's safety profile and pharmacokinetics when administered intravenously as a two-hour infusion every four weeks. The study treated patients on nine dose levels of Triapine and they tolerated the treatment well, the company said, allowing further studies. Vion said it planned to continue enrolling patients into a second Phase I trial of Triapine administered daily for five days every four weeks. Other Phase I studies are planned, the company said.